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NMD can be recommended when eight sub-scales are used and reported. The
suggestion that the SF-36 can be utilized as a two-sub-scale measure of physical
health and mental health components in this clinical group, however, was not
supported because of model fit limitations.
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OBJECTIVES: Quality of life (QoL) is an important psychological dimension in pa-
tients with Parkinson’s disease (PD). The factor structure of the SF-36 in patients
with PD was investigated to determine how this measure might best be used to
assess QoL in this clinical population. METHODS: Confirmatory factor analyses
were conducted on self-report SF-36 data from 339 individuals diagnosed with PD.
Six structural models of the SF-36 were evaluated against data. RESULTS: The
underlying factor structure of the SF-36 in PDwas found to be inconsistentwith the
assumedmeasurement model of SF-36 but consistent with contemporary theoret-
ical models of the instrument. CONCLUSIONS: The use of the SF-36 in individuals
with PD can be recommendedwhen eight subscales are used and reported. The use
of the instrument as a two-subscale measure of physical health andmental health
components, however, was not found.
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OBJECTIVES:The purpose of this studywas to investigate changes in health related
quality of life (HRQOL) experienced by patients with multiple sclerosis (MS) and to
determine their experiences, opinions, and expectations related to disease modi-
fying drugs (DMDs) used in MS. METHODS: A sample of 18 individuals with con-
firmed diagnosis of MS was recruited through a university hospital-based neurol-
ogy clinic. Four focus group (FG) sessions involving semi-structured interviews
were conducted. The FG discussions were audio-recorded and were later tran-
scribed for coding purpose. Qualitative content analysis of transcribed data was
performed by two blinded reviewers using QSR NVivo 8 software. The data were
coded into specific themes as per the research questions. RESULTS: Qualitative
analysis indicated twelve major themes related to HRQOL associated with the dis-
ease condition and experiences with the DMDs used to treat MS: (1) HRQOL before
the diagnosis of MS; (2) HRQOL after the diagnosis of MS; (3) Coping with MS; (4)
Opinions regarding the current DMDs; (5) Clinical benefits; (6) Adverse events as-
sociated with the DMDs; (7) Side effects associated with DMDs; (8) Treatment ad-
herence; (9) Convenience of DMD administration; (10) Treatment satisfaction; (11)
Expectations from the future DMDs; and (12) Cost associatedwith DMDs. HRQOL in
social, physical, and psychological domains declined considerably among all par-
ticipants since the diagnosis of MS. Participants were content with clinical benefits
associated with DMDs they were currently taking. Future DMDs were expected to
be safer and easier to administer. CONCLUSIONS: This study provides an in-depth
understanding of the various factors that affect HRQOL of patients living with MS
and the characteristics of DMDs that are ofmost value toMS patients. Study results
support the need to determine patient preferences for specific adverse events as-
sociated with DMDs against the clinical benefits in order to improve adherence
with DMDs and consequent outcomes.
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OBJECTIVES: To assess the impact of the Medicare Part D coverage gap and co-pay
levels on medication utilization behaviors among beneficiaries taking disease
modifying drugs (DMDs) for the treatment of multiple sclerosis (MS).METHODS: A
retrospective cohort study was conducted using a 5% national sample of Medicare
beneficiaries for 2007. Ambulatory patients diagnosed with MS and taking at least
one DMD were included. Adherence was measured using proportion of days cov-
ered (PDC). Patients were classified as discontinuing therapy if last day of posses-
sion was more than 60 days before the end of the year. Low income subsidy (LIS)
status was used as a measure of out-of-pocket burden. RESULTS: 1,439 beneficia-
ries with MS and DMD use were identified. 89% reached the coverage gap and 81%
reached catastrophic coverage. Average time in gap was 2 to 4 months for the
different copay groups. Overall PDC measures were 85.7% pre-gap, 81.7% during
gap, and 87.3% in catastrophic coverage. PDC for full year was higher (p0.001) for
no-copay LIS (90.2%) than for reduced-copay LIS (83.7%) and full-copay (79.8%)
beneficiaries. Full-copay beneficiaries were slightly more likely to stop therapy
after hitting the gap than were reduced-copay or no-copay beneficiaries (17.7%,
15.0%, 10.6%). Full-copay beneficiaries were more likely (p0.001) than reduced-
copay or no-copay beneficiaries to have a drop in PDC during the coverage gap
(46.3%, 28.2%, 18.1%). CONCLUSIONS:Most beneficiaries with MS reach the cover-
age gap early in the year and fairly quickly move to catastrophic coverage. Average
time in the coverage gap is limited, but significantly reduces adherence. Higher
out-of-pocket burden is also associated with a reduction in adherence.
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OBJECTIVES: Once-daily armodafinil significantly improves wakefulness in pa-
tients with excessive sleepiness due to shift work disorder (SWD), treated obstruc-
tive sleep apnea (OSA), or narcolepsy. The objective of the current analysis was to
examine resource utilization by patients who received armodafinil for these FDA-
approved indications.METHODS: Data were collected from the IMS LifeLink Data-
base (December 2008 to March 2010) and contained longitudinal patient data from
medical claims (diagnostic/therapeutic services), pharmacy claims (prescriptions),
and eligibility files (demographics and enrollment). Patients were identified and
healthcare utilization data were collected for 6months before and up to 10months
after their first armodafinil pharmacy claim. Healthcare costs and visits before and
after initiation of armodafinil were statistically analyzed using paired t-tests.
RESULTS: 1,282 patients were included (4.5% SWD; 85.9% OSA; 20.4% narcolepsy).
The mean monthly healthcare cost for patients prior to taking armodafinil was
$1,562.99 (pharmacy $432.26; medical $1,130.73). After armodafinil initiation, over-
all monthly cost decreased to $1,438.11 (p0.0588). Armodafinil significantly in-
creased prescription costs by $138.53/month (p0.0001) but decreased medical
costs by $263.41/month (p0.0001). Medical costs were decreased by $133.23 for
physician costs (p0.0001) and $75.62 for outpatient costs (p0.0039). Emergency
room costs were lower by $3.99/month (NS), and inpatient costs were lower by
$7.51/month (NS). The number of inpatient visits were reduced by 0.21/year
(p0.0307), physician visits by 4.91/year (p0.0001), and outpatient visits by 0.89/
year (p0.0001). CONCLUSIONS: After armodafinil treatment, reductions were
seen in healthcare utilization and costs compared to the pre-armodafinil period. As
expected, total prescription costs were greater following initiation of armodafinil
therapy; however, lower total monthly costs were observed with armodafinil be-
cause use of medical resources decreased. This significant reduction in medical
resource utilization appeared to be driven predominantly by fewer physician visits
and lower outpatient costs. This research was sponsored by and conducted in
collaboration with Cephalon, Inc., Frazer, PA.
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OBJECTIVES: Uncontrolled epilepsy is associated with devastating injuries, neuro-
psychiatric impairment, and increased mortality based on clinical observations.
The purpose of this study is to evaluate the clinical and economic burden of un-
controlled epilepsy in a Medicaid population. METHODS: Medical and pharmacy
claims from Florida (1997Q3-2008Q2), Iowa (1998Q1-2006Q2), Kansas (2001Q1-
2009Q2), Missouri (1997Q1-2008Q2), and New Jersey (1997Q1-2008Q4) Medicaid da-
tabaseswere analyzed. Patients18 yearswith epilepsy and receiving antiepileptic
drugs (AEDs) were selected. A retrospective matched-cohort design was used to
classify patients intomutually-exclusive cohorts of “uncontrolled” (2 consecutive
AED changes followed by 1 epilepsy-related inpatient/ER visit), “well-controlled”
(no AED change and no epilepsy-related inpatient/ER visit) and “intermediate”
(neither “uncontrolled” nor “well-controlled”) epilepsy. Patients with uncontrolled
epilepsy were matched 1:1 with those with well-controlled and intermediate epi-
lepsy, respectively, using propensity score matching. Matched cohorts were com-
pared for health care resource utilization, occurrence of negative clinical events,
and direct health care costs. Statistical differences between cohorts were assessed
using multivariate conditional regression models, adjusted for demographics,
treatment characteristics, and comorbidities. RESULTS:Uncontrolled epilepsywas
associated with significantly higher health care resource utilization (adjusted rate
ratios [ARRs] [95% confidence intervals (95%CIs)]: hospitalizations6.65 [6.41-6.90],
length of hospital stays7.72 [7.60-7.84], emergency-room visits3.67 [3.61-3.74],
outpatient visits3.85 [3.77-3.93]) versus well-controlled epilepsy. Morbidity oc-
curred more frequently in the uncontrolled group (ARRs: fractures: 2.16 [2.07-2.26],
motor vehicle accident-related injuries: 2.45 [1.77-3.40], head injuries: 2.09 [2.04-
2.14], status epilepticus events: 9.71 [8.20-11.50]) relative to well-controlled pa-
tients. Patients with uncontrolled epilepsy also incurred higher health care costs
(adjusted cost difference [95%CI]$12,258 [$10,482-$14,083] per patient per year), of
which hospitalization costs represented 46.3%. Results were similar when com-
pared to intermediate epilepsy. CONCLUSIONS: Uncontrolled epilepsy was associ-
atedwith significantly greater health care resource utilization, higher rates ofmor-
bidity, and higher medical costs compared to well-controlled and intermediate
epilepsy.
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OBJECTIVES: Identify the frequency, severity, and cost of relapses among a multi-
ple sclerosis (MS) population. METHODS: Data was assessed from MarketScan®
Research Database. Patients at least 18 years old with MS, defined at least 2 outpa-
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